A Multicenter Phase II Study of Twice|Weekly Bortezomib plus ...

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

This was a multicenter, randomized, open-label, active-controlled, phase 3 trial. The trial protocol, which is available at NEJM.org, was ...

A multicenter Phase II study of bortezomib in recurrent or metastatic ...

Patients were not allowed to have received previous chemotherapy for metastatic disease. The initial dose of bortezomib was a 1.5 mg/m2 intravenous push twice ...

Efficacy and safety of oral panobinostat plus subcutaneous ...

Chari, A ∙ Cho, HJ ∙ Dhadwal, A ∙ et al. A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma ... a multicentre, ...

Clinical Trials Using Bortezomib - NCI

This phase II trial compares the combination of selinexor, daratumumab, velcade (bortezomib), and dexamethasone (Dara-SVD) to the usual treatment of daratumumab ...

A multicenter Phase II study of bortezomib in recurrent or metastatic ...

... twice weekly for 2 weeks, followed by 1 week of rest. A cycle of therapy consisted of 4 doses of bortezomib over 21 days. Dose escalation to ...

Who is this study for? - Patients with Multiple Myeloma - MediFind

A PHASE II MULTI-CENTRE, RANDOMIZED, OPEN LABEL STUDY OF PROLONGED THERAPY WITH SC BORTEZOMIB TWICE MONTHLY ASSOCIATED WITH DEXAMETHASONE, IN RELAPSED AND ...

Clinical perspectives on the optimal use of lenalidomide plus ...

The randomized phase II EVOLUTION trial, which included lenalidomide and bortezomib with weekly dexamethasone treatment (the so-called VRd ...

Research and trials - Orphanet

A Multicenter Phase II Study of Subcutaneous Velcade Plus Oral Melphalan and ... A Multicenter, Open Label Study Of Weekly Carfilzomib ...

Clinical activity of bortezomib in relapsed/refractory MALT lymphomas

40. de Vos, S. ∙ Goy, A. ∙ Dakhil, S.R. ... Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with ...

[PDF] Randomized, multicenter, phase 2 study (EVOLUTION) of ...

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated ...

Phase-I/II Study of Bortezomib in Combination with Carboplatin and ...

Methods. Patients were assigned to three dose levels of weekly bortezomib with the fixed standard doses of carboplatin AUC 6 and bevacizumab (15 mg/kg) every ...

UMIN-CTR Clinical Trial

... (A multicenter clinical phase II trial, JMSG-0902). Acronym. Weekly bortezomib + dexamethasone therapy for elderly patients with relapsed or ...

Evolution of carfilzomib dose and schedule in patients with multiple ...

Safety and efficacy results from phase I and II trials informed the study design of the phase III trials. BSC, best supportive care; BTZ, bortezomib; Cd, ...

Bortezomib for the Treatment of Hematologic Malignancies

... twice weekly to once weekly in combination regimens did not ... bortezomib: results of a multicentre phase 2 clinical trial. Br J ...

Combined therapy with ibrutinib and bortezomib followed by ...

∙ et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006; 24:4867 ...

MSAG Update - Bortezomib, Lenalidomide and Dexamethasone (VRd)

... studies[1, 3] utilize a twice-weekly intravenous bortezomib schedule. ... Kumar, S., et al., Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of ...

Phase II Study of Lenalidomide, Subcutaneous Bortezomib, and ...

In the Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RsqVD) study, a multicenter ... plus the addition of SQ bortezomib twice monthly in high-risk ...

Velcade® (bortezomib) - OHSU

27. Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.

Phase I trial of weekly and twice-weekly bortezomib with rituximab ...

Of the 57 patients in this phase I trial, 55 participated in 1 of 2 dosing schedules that included rituximab (375 mg/m(2)) and cyclophosphamide (750 or 1,000 mg ...

Paper: GEM2017FIT Trial: Induction Therapy with ... - Abstract

denotes that this is a ticketed session. 209 GEM2017FIT Trial: Induction Therapy with Bortezomib ... 2 and at 56 mg/m2 weekly since C3. R was ...